Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study.
暂无分享,去创建一个
[1] K. Krishnan,et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. , 2004, The American journal of psychiatry.
[2] A. Leentjens. Depression in Parkinson’s Disease: Conceptual Issues and Clinical Challenges , 2004, Journal of geriatric psychiatry and neurology.
[3] S. Beyenburg,et al. "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. , 2004, The Journal of clinical psychiatry.
[4] H. Marín,et al. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. , 2004, The Journal of neuropsychiatry and clinical neurosciences.
[5] S. Grill,et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis , 2004, Neurology.
[6] D. Weintraub. Diagnosing and Treating Depression in Patients With Parkinson's Disease , 2004 .
[7] A. Leentjens,et al. SSRIs in the treatment of depression in Parkinson's disease , 2003, International journal of geriatric psychiatry.
[8] A. Albanese. Diagnostic criteria for Parkinson's disease , 2003, Neurological Sciences.
[9] R. Roos,et al. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. , 2002, British journal of clinical pharmacology.
[10] David Eidelberg,et al. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. , 2002, The American journal of psychiatry.
[11] S. Chiechio,et al. The SSRI, Citalopram, Improves Bradykinesia in Patients With Parkinson's Disease Treated with L-Dopa , 2002, Clinical neuropharmacology.
[12] S Mazumdar,et al. A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. , 2001, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[13] G. Dell''Agnello,et al. SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study , 2001, Clinical neuropharmacology.
[14] L. Murri,et al. Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms , 2000, Neurology.
[15] D. Arciniegas,et al. The neuropsychiatry of pathologic affect: an approach to evaluation and treatment. , 2000, Seminars in clinical neuropsychiatry.
[16] C. Mariani,et al. Tolerability of paroxetine in Parkinson's disease: A prospective study , 2000, Movement disorders : official journal of the Movement Disorder Society.
[17] K. Krishnan,et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. , 2000, The Journal of clinical psychiatry.
[18] R. Donahue,et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. , 2000, The Journal of clinical psychiatry.
[19] C. Clary,et al. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. , 2000, The American journal of psychiatry.
[20] F. J. Arranz,et al. Effects of comorbidity and polypharmacy on the clinical usefulness of sertraline in elderly depressed patients: an open multicentre study. , 1997, Journal of affective disorders.
[21] Roger Kurlan,et al. A survey of antidepressant drug use in Parkinson's disease , 1997, Neurology.
[22] R. Hauser,et al. Sertraline for the treatment of depression in parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.
[23] R. Leiguarda,et al. Cognitive functions in major depression and Parkinson disease. , 1997, Archives of neurology.
[24] M. Bromberg,et al. A self report measure of affective lability , 1997, Journal of neurology, neurosurgery, and psychiatry.
[25] A. Rush,et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties , 1996, Psychological Medicine.
[26] Matthew A. Menza,et al. Parkinson's disease and anxiety: Comorbidity with depression , 1993, Biological Psychiatry.
[27] H. Mayberg,et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease , 1990, Annals of neurology.
[28] A. Rush,et al. The inventory for depressive symptomatology (IDS): Preliminary findings , 1986, Psychiatry Research.
[29] R. Mayeux,et al. Altered serotonin metabolism in depressed patients with Parkinson's disease , 1984, Neurology.
[30] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[31] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.
[32] M. Hamilton. The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.
[33] R. Reitan. Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .
[34] S. Gershon,et al. Dopamine and depression , 2005, Journal of Neural Transmission / General Section JNT.
[35] S. Gilman,et al. Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.
[36] P. Bech,et al. Depression in idiopathic Parkinson's disease treated with citalopram: A placebo-controlled trial , 1998 .
[37] M. First,et al. Structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version : scoresheet , 1997 .
[38] R. R. Abidin. Psychological Assessment Resources , 1995 .
[39] H. Mayberg,et al. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. , 1992, The Journal of neuropsychiatry and clinical neurosciences.
[40] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[41] S. Fahn. Unified Parkinson's Disease Rating Scale , 1987 .